Biological function and prognostic significance of peroxisome proliferator-activated receptor δ in rectal cancer

Clinical Cancer Research

Volumn 17, Issue 11, 2011, Pages 3760-3770

  Yang, Lie ^a,b   Zhang, Hong ^c   Zhou, Zong Guang ^a   Yan, Hui ^a   Adell, G ^d   Sun, Xiao Feng ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UNIVERSITY OF SKÖVDE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECTUM CANCER; RECTUM MUCOSA; TISSUE MICROARRAY;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MUCOUS MEMBRANE; NEOPLASM PROTEINS; PPAR DELTA; PROGNOSIS; PROTEIN TYROSINE PHOSPHATASES; RECTAL NEOPLASMS;

EID: 79957887976     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2779     Document Type: Article

References (39)

1. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 1994;91:7355-9. (Pubitemid 24226862)
2. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:201.
3. Kota BP, TH Huang, BD Roufogalis. An overview on biological mechanisms of PPARs. Pharmacol Res 2005;51:85-94. (Pubitemid 40040538)
4. Peters JM, Gonzalez FJ. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochim Biophys Acta 2009;1796:230-41.
5. Takahashi S, Tanaka T, Kodama T, Sakai J. Peroxisome proliferator- activated receptor δ (PPARδ), a novel target site for drug discovery in metabolic syndrome. Pharmacol Res 2006;53:501-7.
6. He TC, Timotly AC, Bert V, Kinzler KW. PPARd is an APC regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45. (Pubitemid 29519912)
7. min/+ mice proportionally to their tumor inhibitory effect: implications for the role of PPARd in carcinogenesis. Carcinogenesis 2006;27:232-9.
8. Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan CY, Xu X, et al. Expssion of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer 2006;95:889-95. (Pubitemid 44498105)
9. Peters JM, Hollingshead HE, Gonzalez FJ. Role of peroxisome-proliferator- activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin Sci (Lond) 2008;115:107-27.
10. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci U S A 2001;98:2598-603. (Pubitemid 32209528)
11. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 2004;10:245-7. (Pubitemid 38667613)
12. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome. Cancer Cell 2004;6:285-95.
13. Reed KR, Sansom OJ, Hayes AJ, Gescher AJ, Winton DJ, Peters JM, et al. PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 2004;23:8992-6. (Pubitemid 39657790)
14. Chen LC, Hao CY, Chiu YS, Wong P, Melnick JS, Brotman M, et al. Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res 2004;64:3694-700. (Pubitemid 38657950)
15. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001;61:3124-30. (Pubitemid 32691964)
16. Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, et al. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res 2006;66:4394-401.
17. Hollingshead HE, Borland MG, Billin AN, Willson TM, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-b/d (PPARb/d) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 2008;29:169-76. (Pubitemid 351201756)
18. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, et al. Effects of peroxisome proliferator-activated receptor β on placentation, adiposity, and colorectal cancer.Proc Natl Acad Sci U S A 2002;99:303-8.
19. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 2004;10:481-3. (Pubitemid 38667905)
20. Yang L, Olsson B, Pfeifer D, Jönsson JI, Zhou ZG, Jiang X, et al. Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell-fibronectin adhesion of colon cancer cells. Oncogene 2010;29:516-26.
21. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980-7.
22. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, et al. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
23. Adell G, Zhang H, Evertsson S, Sun XF, Stål OH, Nordenskjöld BA, et al. Apoptosis in rectal cancer: prognosis and recurrence after preoperative radiotherapy. Cancer 2001;91:1870-75. (Pubitemid 32424113)
24. Adell G, Zhang H, Jansson A, Sun XF, Stål OH, Nordenskjöld BA, et al. Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 2001;50:659-63. (Pubitemid 32515323)
25. Knutsen A, Adell G, Sun XF. Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:149-55. (Pubitemid 39165479)
26. ÅSA RW, Joar S, Gunnar A, Sun XF. Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy. Int J Radiation Oncology Biol Phys 2006;65:452-8.
27. Pachkoria K, Zhang H, Adell G, Jarlsfelt I, Sun XF. Cox-2 expression in rectal cancer patients with or without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:739-44. (Pubitemid 41400060)
28. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 1988;48:6863-71. (Pubitemid 19012219)
29. Yoshinaga M, Kitamura Y, Chaen T, Yamashita S, Tsuruta S, Hisano T, et al. The simultaneous expression of peroxisome proliferator-activated receptor delta and cyclooxygenase-2 may enhance angiogenesis and tumor venous invasion in tissues of colorectal cancers. Dig Dis Sci 2009;54:1108-14.
30. Knutsen HK, Olstørn HB, Paulsen JE, Husøy T, Goverud IL, Løberg EM, et al. Increased levels of PPARbeta/delta and cyclin D1 in flat dysplastic ACF and adenomas in Apc(Min/+) mice. Anticancer Res 2005;25:3781-9.
31. Foreman JE, Sorg JM, McGinnis KS, Rigas B, Williams JL, Clapper ML, et al. Regulation of peroxisome proliferator-activated receptor-β/δ by the APC/β-catenin pathway and nonsteroidal antiinflammatory drugs. Mol Carcinog 2009;48:942-52.
32. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor β in colorectal cancer. Proc Natl Acad Sci U S A 2000;97:13275-80.
33. Pang MY, de la Monte SM, Longato L, Tong M, He J, Chaudhry R, et al. PPARδ agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol 2009;50:1192-201.
34. Nahlé Z, Hsieh M, Pietka T, Coburn CT, Grimaldi PA, Zhang MQ, et al. CD36-dependent regulation of muscle FoxO1 and PDK4 in the PPAR delta/beta-mediated adaptation to metabolic stress. J Biol Chem 2008;283:14317-26.
35. Ishizuka M, Sawada T, Okada T, Nagata H, Takagi K, Horie T, et al. Influence of tumor peroxisome proliferator-activated receptor gamma and delta expression on postoperative mortality of patients undergoing colorectal cancer surgery. J Invest Surg 2009;22:105-11.
36. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009;74:673-88.
37. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010;29:781-8.
38. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, et al. An antiapoptotic protein human survivin is a direct inhibitor of caspase-3 and 7. Biochemistry 2001;40:1117-23. (Pubitemid 32108606)
39. Yang L, Zhou ZG, Zheng XL, Wang L, Yu YY, Zhou B, et al. RNA interference against peroxisome proliferator-activated receptor δ gene promotes proliferation of human colorectal cancer cells. Dis Colon Rectum 2008;51:318-26. (Pubitemid 351972460)